Home › Funds › Boxer Capital Management, LLC › CYTK
Boxer Capital Management, LLC position in CYTK
CYTOKINETICS INC · Health Care
Boxer Capital Management, LLC reported holding 100,000 shares of CYTK (CYTOKINETICS INC) in its Q2 2026 13F filing — a position valued at US$8.5M, representing 0.64% of its reported portfolio and ranking #29 among its reported holdings. Boxer Capital Management, LLC has disclosed CYTK holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Boxer Capital Management, LLC's CYTK position evolved
Boxer Capital Management, LLC first disclosed a stake in CYTK in Q3 2025 at 200,000 shares (US$11.0M). Across 4 filings, Boxer Capital Management, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 100,000 shares valued at US$8.5M. Notable position changes include a 50% trim in Q4 2025 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 200.00K | $10.99M | New |
| Q4 2025 | 100.00K | $6.35M | Reduce |
| Q1 2026 | 100.00K | $6.59M | Hold |
| Q2 2026 | 100.00K | $8.52M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 52 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M sh · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M sh · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M sh · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M sh · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M sh · $102.34M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $83.52M · Q2 2026
- GW&K Investment Management, LLC 916.11K sh · $78.04M · Q2 2026
- Melqart Asset Management (UK) Ltd 767.52K sh · $65.39M · Q2 2026
- Siren, L.L.C. 758.95K sh · $64.66M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
More on Boxer Capital Management, LLC
FAQ
How long has Boxer Capital Management, LLC held CYTK?
Boxer Capital Management, LLC has disclosed CYTK holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Boxer Capital Management, LLC's current position in CYTK?
As of Q2 2026, Boxer Capital Management, LLC holds 100.00K shares of CYTK (CYTOKINETICS INC), valued at $8.52M, representing 0.64% of its reported portfolio and ranking #29.
Has Boxer Capital Management, LLC been buying or selling CYTK?
In the latest 13F filing (Q2 2026), Boxer Capital Management, LLC held unchanged its position in CYTK.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.